Plain-English translation of NCT06610825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This Phase II trial is testing a medication called Fam-Trastuzumab Deruxtecan-Nxki () for men with advanced prostate cancer that has spread to other parts of the body and is no longer responding to standard hormone treatments. The study will enroll 60 participants to see whether this medication can slow or stop the cancer's growth and how well patients tolerate it. This treatment targets a specific protein on cancer cells, offering a different approach from traditional chemotherapy.
Many men with advanced prostate cancer eventually stop responding to hormone-blocking drugs, leaving them with limited options—especially if they cannot tolerate or choose not to receive chemotherapy. This trial exists to see whether this medication, which works in a targeted way, can help these patients and give them another treatment choice.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion at a clinic or hospital. The trial will track how well the medication works, monitor you for side effects, and measure your quality of life over time through regular visits and blood tests. Researchers will also assess whether your cancer shrinks or stops growing during treatment.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Washington D.C. Veterans Affairs Medical Center
Collaborators
Daiichi Sankyo, Cancer Research And Biostatistics
Enrollment target
~60 participants
Started
March 2025
Primary completion
October 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Asha Escobar
Washington DC VA Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.